SOURCE: The Bedford Report

The Bedford Report

September 07, 2011 08:16 ET

Marina Biotech and OXiGENE Attack Cancer From Different Angles

The Bedford Report Provides Equity Research on Marina Biotech & OXiGENE

NEW YORK, NY--(Marketwire - Sep 7, 2011) - Cancer, projected by the World Health Organisation to become the leading cause of death worldwide this year, has already emerged as the most expensive disease, costing the global economy nearly a trillion dollars a year. With cancer drugs alone costing the United States more than $30 billion a year, it is clearly a lucrative sector for drug developers. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on Marina Biotech, Inc. (NASDAQ: MRNA) and OXiGENE, Inc. (NASDAQ: OXGN). Access to the full company reports can be found at:

While the positive fundamentals are there, over the last month cancer drug stocks have suffered from what MarketWatch's Val Brickates Kennedy calls the "Dendreon Effect." The article reports that biotech companies whose stocks have taken heavy hits include those that are at early stages of marketing new treatments.

"Pretty much every company that had just launched a product or was about to launch a product got crushed," Leerink Swann analyst Howard Liang explains.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

OXiGENE is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat cancer and eye diseases. Cancer medication is an inherently risky sector. Earlier this year Reuters published research from BioMed Tracker and BIO, which claims that the cancer drug success rate is a mere 4.7 percent.

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. Marina Biotech entered into an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information